-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor Today, Arkuda Therapeutics announced the completion of a $64 million Series B financing
.
Funding will be used to advance its flagship progranulin enhancer program into studies supporting the IND application
.
The company's small molecule platform targets the interface of lysosomal and microglia biology and can be used to treat a variety of rare and common neurological diseases
.
Arkuda is working to develop a small molecule therapy that modulates progranulin, which plays an important role in lysosomal function and innate immunity in the brain
.
The initial indication for the company's lead therapy is GRN-related frontotemporal dementia (FTD-GRN), a severe inherited neurodegenerative disease
.
Loss of progranulin and brain lysosome dysfunction are caused by mutations in the GRN gene that encodes pregranulin
.
Arkuda's small-molecule drug can correct the loss of granulin precursors to improve lysosomal function and has the potential to provide clinical benefit in patients with FTD-GRN
.
The company has developed potent lead compounds that penetrate the brain
.
Image credit: Arkuda's website The company also plans to explore the compounds' efficacy in a variety of neurodegenerative diseases, including Alzheimer's and Parkinson's disease
.
"This Series B financing is an important milestone
.
We will work to advance a potential 'first-in-class' granulin precursor enhancer program into studies that support IND filings and expand our pipeline to target lysosomal dysfunction, which is key to a variety of neurodegenerative diseases driving factor
.
"This funding round will allow us to accelerate the process of translating our emerging understanding of lysosomal biology into effective therapeutics," said Arkuda co-founder, president and CEO Dr.
Gerhard Koenig
.
"Reference: [1] Lilly, Pfizer-backed Arkuda bags $64M to test drug in frontotemporal dementia in 2023.
Retrieved February 10, 2022, from https:// arkuda-bags-64m-to-test-drug-frontotemporal-dementia-2023[2] ARKUDA THERAPEUTICS RAISES $64 MILLION SERIES B FINANCING TO ADVANCE PIPELINE OF PROGRAMS TARGETING LYSOSOMAL BIOLOGY TO TREAT NEURODEGENERATIVE DISEASES.
Retrieved February 10, 2022, from https: https:// Disclaimer: The WuXi AppTec content team focuses on introducing the progress of global biomedical health research
.
This article is for information exchange purposes only.
The views in this article do not represent WuXi AppTec's position, nor do they support or oppose the views in the article
.
This article is not a treatment Program recommendation
.
If you need treatment program guidance, please go to a regular hospital for treatment
.
.
Funding will be used to advance its flagship progranulin enhancer program into studies supporting the IND application
.
The company's small molecule platform targets the interface of lysosomal and microglia biology and can be used to treat a variety of rare and common neurological diseases
.
Arkuda is working to develop a small molecule therapy that modulates progranulin, which plays an important role in lysosomal function and innate immunity in the brain
.
The initial indication for the company's lead therapy is GRN-related frontotemporal dementia (FTD-GRN), a severe inherited neurodegenerative disease
.
Loss of progranulin and brain lysosome dysfunction are caused by mutations in the GRN gene that encodes pregranulin
.
Arkuda's small-molecule drug can correct the loss of granulin precursors to improve lysosomal function and has the potential to provide clinical benefit in patients with FTD-GRN
.
The company has developed potent lead compounds that penetrate the brain
.
Image credit: Arkuda's website The company also plans to explore the compounds' efficacy in a variety of neurodegenerative diseases, including Alzheimer's and Parkinson's disease
.
"This Series B financing is an important milestone
.
We will work to advance a potential 'first-in-class' granulin precursor enhancer program into studies that support IND filings and expand our pipeline to target lysosomal dysfunction, which is key to a variety of neurodegenerative diseases driving factor
.
"This funding round will allow us to accelerate the process of translating our emerging understanding of lysosomal biology into effective therapeutics," said Arkuda co-founder, president and CEO Dr.
Gerhard Koenig
.
"Reference: [1] Lilly, Pfizer-backed Arkuda bags $64M to test drug in frontotemporal dementia in 2023.
Retrieved February 10, 2022, from https:// arkuda-bags-64m-to-test-drug-frontotemporal-dementia-2023[2] ARKUDA THERAPEUTICS RAISES $64 MILLION SERIES B FINANCING TO ADVANCE PIPELINE OF PROGRAMS TARGETING LYSOSOMAL BIOLOGY TO TREAT NEURODEGENERATIVE DISEASES.
Retrieved February 10, 2022, from https: https:// Disclaimer: The WuXi AppTec content team focuses on introducing the progress of global biomedical health research
.
This article is for information exchange purposes only.
The views in this article do not represent WuXi AppTec's position, nor do they support or oppose the views in the article
.
This article is not a treatment Program recommendation
.
If you need treatment program guidance, please go to a regular hospital for treatment
.
